secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eloxx Pharmaceuticals, Inc. (ELOX)
CIK:        0001035354
Form:       8-K
Filed at:   2024-03-14T23:59:59+00:00
Accession:  0001104659-24-034529
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Eloxx inks exclusive license deal with Almirall for ZKN-013; $3M upfront, up to $470M milestones
--------------------------------------------------------------------------------

- Upfront payment of $3.0 million; eligible for up to $470.0 million in regulatory and sales milestones.
- Tiered royalties on any future global sales of ZKN-013.
- ZKN-013 is a Phase I ready oral therapy for nonsense mutations causing rare dermatologic diseases.
- Almirall obtains worldwide rights to develop and commercialize ZKN-013.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1035354/000110465924034529/0001104659-24-034529-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1035354/000110465924034529/tm248887d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-034529

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer